Tucidinostat

Tucidinostat
Clinical data
Trade names	Epidaza
Other names	Tucidinostat
Identifiers
	IUPAC name N-(2-Amino-5-fluorophenyl)-4-[[[1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]-benzamide;
CAS Number	1616493-44-7 ;
PubChem CID	9800555;
ChemSpider	7976319;
UNII	87CIC980Y0;
CompTox Dashboard (EPA)	DTXSID701032295 ;
Chemical and physical data
Formula	C22H19FN4O2
Molar mass	390.418 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC1=C(NC(=O)C2=CC=C(CNC(=O)\C=C\C3=CN=CC=C3)C=C2)C=C(F)C=C1;
	InChI InChI=1S/C22H19FN4O2/c23-18-8-9-19(24)20(12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+; Key:WXHHICFWKXDFOW-BJMVGYQFSA-N;

Chidamide (Epidaza) is a histone deacetylase inhibitor (HDI) developed wholly in China.^[1] It was also known as HBI-8000.^[2] It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.^[3]

Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and has orphan drug status in Japan.^[2]^{[better source needed]} As of April 2015^[update] it is only approved in China.^[1]

Chidamide is being researched as a treatment for pancreatic cancer.^[4]^[5]^[6] However, it is not US FDA approved for the treatment of pancreatic cancer.

References

^ ^a ^b Lowe, Derek (April 2015). "China's First Homegrown Pharma". Seeking Alpha. {{cite web}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ ^a ^b "Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China". PR Newswire Association LLC.
^ "HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai". PR Newswire Association LLC. February 2016.
^ Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, et al. (April 2013). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
^ Guha M (April 2015). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews. Drug Discovery. 14 (4): 225–6. doi:10.1038/nrd4583. PMID 25829268. S2CID 36758974.
^ Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015. {{cite news}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[SA2015-1] Lowe, Derek (April 2015). "China's First Homegrown Pharma". Seeking Alpha. {{cite web}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[FBT2016-2] "Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China". PR Newswire Association LLC.

[3] "HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai". PR Newswire Association LLC. February 2016.

[Qiao2013-4] Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, et al. (April 2013). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochemical and Biophysical Research Communications. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.

[Guha2015-5] Guha M (April 2015). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews. Drug Discovery. 14 (4): 225–6. doi:10.1038/nrd4583. PMID 25829268. S2CID 36758974.

[6] Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015. {{cite news}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[1]

[2]

[3]

[4]

[5]

[6]